Receipt date: 08/11/2008 | Docket No.: RLL-293US | Serial No.: 10/552,456

INFORMATION DISCLOSURE CITATION

AUG 11 2008

Applicants: MEHTA et al.

Filed: 10/7/2005 Group: 1626

U.S. PATENT DOCUMENTS

EXAMINER T	MAG	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
J.N./	S1A1	2,490,714	12/6/1949	Searle	260	239	
	S1A2	5,001,160	3/19/1991	McPherson et al.	514	255	
	S1A3	5,164,402	11/17/1992	Brighty	514	300	
	S1A4	5,179,108	1/12/1993	George et al.	514	319	
	S1A5	6,313,312	11/6/2001	Banks et al.	548	452	
	S1A6	7,288,562	10/30/2007	Mehta et al.	514	412	
	S1A7	2003/0105071	6/5/2003	Cuny et al.	514	210.2	
	S1A8	2003/0162780	8/28/2003	Brotherton-Pleiss et al.	514	235.5	
	S1A9	2003/0171362	9/11/2003	Madera et al.	514	218	
	\$1A10	2006/0287380	12/21/2006	Salman et al.	514	412	
+				10. at 20.			
4						-	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
/J.N./	S1B	CA 2,155,320	8/19/1993	Canada	C07D	211/68	
	\$1B2	EP 0 413 455	2/20/1991	EPO	C07D	401/04	
	S1B3	EP 0 613 232	8/31/1994	EPO	H02M	3/335	
	S1B4	EP 0 863 141	9/9/1998	EPO	C07D	401/06	
	S1B	EP 0 930 298	7/21/1999	.EPO	C07D	211/46	-
	S1B6	WO 98/53814	12/3/1998	PCT	A61K	31/395	
	S1B	WO 99/43657	9/2/1999	PCT	C07D	211/26	
V	S1B8	WO 01/42212	6/14/2001	PCT	C07D	211/48	

EXAMINER /Jason Nolan/

DATE CONSIDERED

09/12/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 PAGE 1 OF $\underline{\mathcal{Y}}$

Receipt date: 08/11/2008

Docket No.: RLL-293US

Serial No.: 10/552,456

INFORMATION DISCLOSURE CITATION
SUPPLEMENTAL

Applicants: MEHTA et al.

Filed: 10/7/2005

Group:

1626

Jan						_	
Sist WO 01/94/893 7/3/2001 PCT C07D 221/24	/J.N./	S1B9	WO 01/42213	6/14/2001	PCT	C07D	211/58
Sist WO 01/90082		S1B10	WO 01/47893	7/5/2001	PCT	C07D	221/24
Sist WO 02/00652 1/3/2002 PCT C07D 241/08		S1B11	WO 01/90081	11/29/2001	PCT	C07D	241/08
Sista		S1B12	WO 01/90082	11/29/2001	PCT	C07D	241/08
Sissis WO 02/04402 1/17/2002 PCT C07C 219/10		S1B13	WO 02/00652	1/3/2002	PCT	C07D	453/02
Siste WO 02/0054241 1/24/2002 PCT C07D 223/16		S1B14	WO 02/04402	1/17/2002	PCT	C07C	219/10
WO 02/051841 7/4/2002 PCT C07D 453/02		S1B15	WO 02/006241	1/24/2002	PCT	C07D	223/16
Sissis		S1B16	WO 02/051841	7/4/2002	PCT	C07D	453/02
WO 03/053495 4/24/2003 PCT C07D 211/26		S1B17	WO 02/053564	7/11/2002	PCT	C07D	453/02
Sisso		\$1818	WO 03/033495	4/24/2003	PCT	C07D	453/02
Sissi		S1B19	WO 03/048124	6/12/2003	PCT	C07D	211/26
WO 2004/04029 1/15/2004 PCT A61K		S1B20	WO 03/048125	6/12/2003	PCT	C07D	211/58
WO 2004/05252 1/15/2004 PCT C07D 209/52		S1B21	WO 2004/004629	1/15/2004	PCT	A61K	
WO 2004/014363 219/2004 PCT A61K 31/40		S1B22	WO 2004/005252	1/15/2004	PCT	C07D	209/52
WO 2004/014635 2/19/2004 PCT C07D 209/52		S1B23	WO 2004/014363	2/19/2004	PCT	A61K	31/40
Sissa		S1B24	WO 2004/014853	2/19/2004	PCT	C07D	209/02
Si827 WO 2004/056767 7/8/2004 PCT C07D 207/14		S1B25	WO 2004/018422	3/4/2004	PCT	C07D	209/52
WO 2004/056810 7/8/2004 PCT C07D 207/14		S1B26	WO 2004/052857	6/24/2004	PCT	C07D	209/52
WO 2004/058810 7/8/2004 PCT C07D 405/12		S1B27	WO 2004/056767	7/8/2004	PCT	C07D	207/14
WO 2004/089811 7/3/2004 PCT C07D 405/12		S182B	WO 2004/056810	7/8/2004	PCT	C07D	405/12
WO 2004/067310 8/12/2004 PCT C07D 209/52		S1B29	WO 2004/056811	7/8/2004	PCT	C07D	405/12
WO 2004/089635 S1972004 PCT C07D 471708		\$1830	WO 2004/067510	8/12/2004	PCT	C07D	209/52
WO 2004/089363 WO 2004/089899 10/21/2004 PCT C07D 209/52		S1B31	WO 2004/069835	8/19/2004	PCT	C07D	471/08
WC 2004/089999 10/21/2004 PCT C07D 209/52		S1B32	WO 2004/089363	10/21/2004	PCT	A61K	31/403
WO 2004/069900 1021/2004 PC1 C07D 209/52		S1B33	WO 2004/089899	10/21/2004	PCT	C07D	209/52
V S1835 WO 2005/092341 10/6/2005 PCT A61K 31/496 L		S1834	WO 2004/089900	10/21/2004	PCT	C07D	209/52
	V	S1835	WO 2005/092341	10/6/2005	PCT	A61K	31/496

EXAMINER

/Jason Nolan/

DATE CONSIDERED

09/12/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 PAGE 2 OF 4

		
Receipt date: 08/11/2008	Docket No.: RLL-293US	Serial No.: 10/552,456
INFORMATION DISCLOSURE CITATION	Applicants: MEHTA et a	1.
SUPPLEMENTAL	Filed: 10/7/2005	Group: 1626

/J.N./ -	S1B36	WO 2006/003587	1/12/2006	PCT	A61K	9/16	1
/J.N./	S1B37	WO 2006/035282	4/6/2006	PCT	A61K	31/439	
/J.N./	S1B38	WO 2006/064304	6/22/2006	PCT	C07D	209/52	
		OTHER DOCUME	NTS (Includ	ding Author, Title, Date, P	ertinent Pa	ages, Etc.)	
/J.N./	S1C1	Brighty et al., "Sy Achiral Diamine",		1 <i>a</i> ,5 <i>a</i> ,6 <i>a</i>)-6-Amino-3-azat 97-1099 (1996)	oicyclo[3.1	.0]hexane, a	Novel
	S1C2	Grover et al., "Ch	iral Mandeli	ic Acid Template Provides nal of Organic Chemistry,			lution for (S)-
	S1C3	Shacklett and Sm	ith, "The Pr	reparation of Substituted E 75:2654-2657 (1953)			al of the
	S1C4	Nkpa and Chedel	kel, "Mecha	nistic Studies on the Addi urnal of Organic Chemistr			•
	S1C5	Kadin and Canno	n, "Esters o	of N-Methyl-3-hydroxypipe nic Chemistry, 27:240-24	ridine Hav		omimetic
	S1C6		"A General,	One-Step Synthesis of a		rs", <i>Synthet</i>	ic
	S1C7		. Vogel's T	extbook of Practical Orga	nic Chemi	stry. 5th Ed	lition. USA:
	S1C8	·		n of Prodrugs. Elsevier.			
	S1C9		ituted piper	Antimuscarinic Activity of azinyl)-2-propanones and 10-616 (1993)			
	S1C10	Carter et al., "Ana Activity of Some S	alogues of C Substituted	Oxybutynin. Synthesis and 7-Amino-1-hydroxy-5-hep ficinal Chemistry, 34(10):3	tyn-2-one	s and Relate	
	S1C11	Wess et al., "Mus antinociception st 72:2047-2054 (20	carinic rece udied with r 103)	ptor subtypes mediating on muscarinic receptor knock	central and cout mice:	peripheral A review", <i>L</i>	,
	S1C12	O'Neill, "Unusual 10(20):1338 (200		antipsychotic-induced dia	abetes", Di	rug Discove	ry Today,
\downarrow	S1C13		sts - a matt	nt of the overactive bladder or of metabolites?", <i>Naun</i>)			

EXAMINER	/Jason Nolan/	DATE CONSIDERED 09/12/2008
	al if reference considered, whether or r e copy of this form with next communi	citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not tion to applicant.

Form PTO-1449 PAGE 3 OF 4

Receipt date: 08/11/2008	Docket No.: RLL-293US	Serial No.: 10/552,456
INFORMATION DISCLOSURE CITATION	Applicants: MEHTA et al	
SUPPLEMENTAL	Filed: 10/7/2005	Group: 1626

J.N. Characteristics of Bladder Muscarinic Receptors", The J Experimental Therapeutics, 248(1):81-88 (1989) Sucis Carrier and Aronstam, "Altered Muscarinic Receptor Pro in Diabetes", The Journal of Pharmacology and Experime 535 (1987) J.N. Sucis Ahren et al., "Blockade of muscarinic transmission increarafter low-dose alloxan challenge in the mouse", Diabetol J.N. Johann et al., "Muscarinic receptors: their distribution and the implications for treating overactive bladder", British J.	perties and Function in the Heart
J.N./ S1C15 Carrier and Aronstam, "Altered Muscarinic Receptor Pro in Diabetes", The Journal of Pharmacology and Experim 535 (1987) J.N./ S1C16 Ahrén et al., "Blockade of muscarinic transmission increar after low-dose alloxan challenge in the mouse", Diabetol.	
/J.N./ in Diabetes", The Journal of Pharmacology and Experime 535 (1987) /J.N./ stc16 Ahrén et al., "Blockade of muscarinic transmission increa after low-dose alloxan challenge in the mouse", Diabetol stc17 Abrams et al., "Muscarinic receptors: their distribution an	
535 (1987) Site	ental Therapeutics, <u>242(</u> 2):531-
Ahrén et al., "Blockade of muscarinic transmission increa after low-dose alloxan challenge in the mouse", Diabetoli sıcız Abrams et al., "Muscarinic receptors: their distribution an	
after low-dose alloxan challenge in the mouse", Diabetol	
sici7 Abrams et al., "Muscarinic receptors: their distribution an	ses the frequency of diabetes
	ogia, 39:383-390 (1996)
ALN / the implications for treating overactive bladder" British J	d function in body systems, and
	ournal of Pharmacology,
148(5):565-578 (2006)	•

EXAMINER: /Jason Nolan/ DATE CONSIDERED 09/12/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.